BiomX (PHGE) was elevated to a Zacks Rank #2 (Buy) following a reassessment of its revenue and earnings projections for 2026. Analysts highlighted the company’s expanding phage therapy pipeline—particularly its lead candidate targeting diabetic foot infections—as a key catalyst. Zacks now forecasts a 35% year-over-year improvement in BiomX’s revenue growth rate driven by potential milestone payments and licensing deals. This upgrade reflects growing confidence that the company’s advanced clinical programs and proprietary BOLT platform can deliver meaningful value before the end of next year.

On December 29, 2025, BiomX secured approximately $3.0 million in gross proceeds through a private placement of Series Y Convertible Preferred Stock and warrants. Each preferred share carries a stated value of $1,000, accrues a 15% annual dividend payable quarterly, and matures in one year. The company also issued warrants exercisable into up to 3.3 million common shares at a $2.00 exercise price with a five-year term. Net proceeds will fund evaluation of the BX011 program for Staphylococcus aureus diabetic foot infections and support general corporate purposes, providing operational flexibility as BiomX explores strategic alternatives.